Additionally, the company launched two new AI-driven products in October 2026 to address emerging regulatory requirements and ...

The TCW Concentrated Large Cap Growth Fund Q3 2026 Commentary details tech sector performance and strategic stock holdings.

Total revenue increased 7% to a record $11.0M from $10.2M in the same prior year period. During 2026, the Company has reduced ...

ArriVent BioPharma, Inc. announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17-targeting antibody-drug conjugate developed in partnership with Lepu Biopharma Co., Ltd. The data, ...

ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...

Responses were deep and durable, with 65% ongoing at clinical cutoff; Results support continued evaluation of the ...

ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, ...

Celebrate our nation’s 250th birthday with a full slate of patriotic music during the Rogue Valley Symphonic Band’s 2026-27 ...

Use BBC.com or the new BBC App to listen to BBC podcasts, Radio 4 and the World Service outside the UK.

Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...

Over 92% of remibrutinib patients remained free from disease progression as assessed by 6-month CDP, showing clinically meaningful delay of nearly 30% vs. teriflunomide with nominal significance¹ ...